Patents by Inventor Yasuo Fukushi

Yasuo Fukushi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybridomas producing monoclonal antibodies to mono-, di- and trifucosylated type 2 chain
    Patent number: 5171667
    Abstract: Hybridoma cell lines that produce monoclonal antibodies that differentially recognize glycolipids with mono-, di-, and trifucosylated type 2 chain structures are disclosed. The monoclonal antibodies can be used to detect specific types of tumor cells that are characterized by enrichment in mono-, di-, or trifucosylated type 2 chain structure. As such, the antibodies produced by the hybridoma cell lines are useful for diagnosis and treatment of human cancer. Also disclosed is an improved method of raising hybridoma cell lines by selecting the hybridomas by positive reactively with one or more fucosylated type 2 chain structures selected from the group consisting of III.sup.3 FucnLc.sub.4, V.sup.3 FucnLc.sub.6, III.sup.3 FucnLc.sub.6, III.sup.3 V.sup.3 Fuc.sub.2 nLc.sub.6, and III.sup.3 V.sup.3 VII.sup.3 Fuc.sub.3 nLc.sub.8.
    Type: Grant
    Filed: July 25, 1989
    Date of Patent: December 15, 1992
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Sen-itroh Hakomori, Yasuo Fukushi
  • Disialofucoganglioside immunogen and fucoganglioside monosialosyl Le.sup.a II
    Patent number: 5011920
    Abstract: Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861) secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.
    Type: Grant
    Filed: May 5, 1989
    Date of Patent: April 30, 1991
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Sen-itiroh Hakomori, Yasuo Fukushi, Edward D. Nudelman, Steven B. Levery
  • Monoclonal antibody that specifically binds to disialosyl Le.sup.a
    Patent number: 4851511
    Abstract: Disialosyl Le.sup.a (IV.sup.3 NeuAcIII.sup.6 NeuAcIII.sup.4 FucLc.sub.4), a novel human cancer-associated fucoganglioside that is highly immunogenic. Also, a hybridoma cell line (ATCC No. HB 8861)secreting a monoclonal IgG3 antibody (FH7) directed to disialosyl Le.sup.a. The disialosyl Le.sup.a antigen was detected in various cancer tissues and their cell lines but was absent in various normal tissues and blood cells. Sera of patients with various cancers, particularly early cases of colonic and gastric cancers, showed an elevated disialosyl Le.sup.a antigen level, which subsequently decreased after surgical tumor removal.
    Type: Grant
    Filed: January 30, 1986
    Date of Patent: July 25, 1989
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Sen-itiroh Hakomori, Yasuo Fukushi, Edward D. Nudelman, Steven B. Levery